Subgroup analysis of the NORDIL trial

J Hypertens. 2002 Jun;20(6):1085-7. doi: 10.1097/00004872-200206000-00018.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Calcium Channel Blockers / adverse effects
  • Calcium Channel Blockers / therapeutic use*
  • Diltiazem / adverse effects
  • Diltiazem / therapeutic use*
  • Humans
  • Hypertension / drug therapy*
  • Myocardial Infarction / etiology
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Stroke / prevention & control
  • Treatment Outcome

Substances

  • Calcium Channel Blockers
  • Diltiazem